JAN 09, 2019 4:01 PM PST

What We Don't Know Won't Hurt Us, Right?

WRITTEN BY: Nicholas Breehl

Myths about gluten are hard to bust. Intolerance, allergy, sensitivity, hypersensitivity. What is what?

Celiac disease is none of these things. It is an autoimmune disorder, where gluten triggers the immune system to attack the gut. It is frequent, lifelong, and can seriously harm health -- but nobody knows for sure what causes it. Now a review in Frontiers in Pediatrics says a common food additive could both create and trigger these autoimmune attacks and calls for warnings on food labels pending further tests.

Environment causes celiac disease -- but only in susceptible individuals.

Gluten-free diets have become popular despite little or no evidence of benefit for most people. But for the 1 in 100 with celiac disease, even a mouthful of bread can trigger an immune response that damages the small intestine, impairing nutrient absorption.

Exactly what causes this autoimmune reaction to gluten -- a protein found in wheat, rye, and barley -- is uncertain. Specific mutations in an essential immunity-related gene called HLA-DQ seem to be necessary for developing celiac disease, with one of two HLA-DQ variants present in virtually every sufferer -- but insufficient, as these variants are also present in about 30% of the general population.

As a result, myriad environmental factors have proposed to interact with genetic risk to cause celiac disease. These span infections, food, and toxins; vaccination, drugs, and surgery. Most recently, food additives have been suggested to contribute. Among these, microbial transglutaminase -- a bacterial enzyme heavily used in industrial processing of meat, dairy, baked and other food products -- has emerged as a likely culprit, according to the new review.

"Microbial transglutaminase can glue together proteins, so it's used to improve food texture, palatability, and shelf-life," says co-author Aaron Lerner, visiting a professor at the Aesku.Kipp Institute in Germany. "This enzyme functions like the transglutaminase produced by our body, which is known to be the target of autoimmunity in celiac disease."

There is a direct positive correlation between the rising use of industrial enzymes in bakery products and increasing incidence of celiac disease in the last four decades, according to Lerner and co-author Dr. Matthias Torsten of the Aesku.KIPP Institute, Germany. But if transglutaminase is produced normally in our tissues -- and by our gut microbes -- what difference should a little more in our diet make?

"This is mostly a question of scale," argues Lerner. "Our own transglutaminase has a different structure to the microbial sort, which allows its activity to be tightly controlled. And while the relatively indiscriminate microbial transglutaminase is produced by some of our normal gut fauna, the amount of the enzyme could be significantly increased when this microbial population is altered by factors like infection, antibiotics, stress or through consumption of industrially processed foods."

What links gluten, transglutaminase, HLA-DQ genes and autoimmunity?

Gluten is difficult to break down completely. This is useful for helping baked goods to rise and keep their shape, but in celiac sufferers presents a problem.

"The gluten protein fragments or 'peptides' that remain after digestion are highly susceptible to transglutaminase, which modifies them to make a variety of new peptides" Lerner explains. "These unusual peptides are particularly likely to resist further breakdown, and to be recognized as 'foreign' by HLA-DQ immune receptors inside the gut wall -- but only in those carrying the HLA-DQ variants associated with celiac disease."

Compounding this, components of gluten also loosen the connections between cells lining the gut, allowing more gluten-derived proteins -- as well as microbial transglutaminase -- to breach this barrier and interact with immune cells.

"Microbial transglutaminase itself could also increase intestinal permeability by directly modifying proteins that hold together the intestinal barrier," adds Lerner.

Human studies implicate microbial transglutaminase

This all begs the question: if it is gluten-derived proteins that stimulate immune cells, why does the immune response target transglutaminase? And are microbial, and human transglutaminase recognized interchangeably by the immune system?

"In one of our own studies, we tested antibodies from the blood of celiac patients. We found that more antibodies were active against complexes of transglutaminase bound to gluten fragments, than against either component alone. The anti-complex antibody count was also the best predictor of intestinal damage in these patients. This was true of both microbial and human transglutaminase complexes, for which there were similar antibody counts."

In other words, microbial transglutaminase (bound to gluten fragments) could be the target of the immune response in celiac disease -- and the attack on our transglutaminase merely a case of mistaken identity. Microbial transglutaminase present in processed foods is, therefore, a potential environmental cause of celiac disease.

Is microbial transglutaminase safe?

But according to Lerner, the jury is still out.

"Ultimately all we have so far are associations between microbial transglutaminase and celiac disease. To test whether this enzyme causes or triggers immune damage in celiac disease will require experimenting with exposure in animal models, intestinal cell lines or biopsies."

Nevertheless, with no known cure for celiac disease, treatment depends on preventive measures -- namely, adhering to a gluten-free diet.

"Until there is a clearer answer, we recommend transparency and vigilance with regards to the labeling of foods processed using microbial transglutaminase."

In Switzerland for example, such products must be labeled as unsuitable for persons with celiac disease.

Sources: Science Daily, Frontiers in Pediatrics, YouTube

About the Author
Master's (MA/MS/Other)
You May Also Like
NOV 14, 2022
Drug Discovery & Development
Experimental Opioid Vaccine Could Prevent Overdose Deaths
Experimental Opioid Vaccine Could Prevent Overdose Deaths
Researchers have developed a vaccine that may be able to block the opioid fentanyl from reaching the brain. They note th ...
DEC 03, 2022
One Molecule Could Make the Difference Between Severe and Mild COVID
One Molecule Could Make the Difference Between Severe and Mild COVID
A case of COVID-19 doesn't cause any symptoms at all in some people, while others are killed by the viral infection. Sci ...
DEC 08, 2022
Clinical & Molecular DX
Circulating Tumor Cells Effectively Inform Treatment Decisions in Patients with Metastatic Breast Cancer
Circulating Tumor Cells Effectively Inform Treatment Decisions in Patients with Metastatic Breast Cancer
Circulating tumor cells are tumor cells found circulating in the blood that come from a primary tumor. Circulating tumor ...
DEC 11, 2022
Drug Discovery & Development
Novel Dermatitis Treatment Produces Long-Term Results in Clinical Trials
Novel Dermatitis Treatment Produces Long-Term Results in Clinical Trials
A monoclonal antibody drug known as rocatinlimab produced significant results in patients with moderate to severe atopic ...
JAN 06, 2023
Investigators Reveal a Surprising Role for a Subset of T Cells
Investigators Reveal a Surprising Role for a Subset of T Cells
T cells are a major component of the adaptive immune system, which forms a kind of memory of the pathogens it reacts to. ...
JAN 13, 2023
B Cell Surface Features Revealed by Advanced Microscopy
B Cell Surface Features Revealed by Advanced Microscopy
With an advanced technique called lattice light sheet microscopy, scientists have revealed structures on the surface of ...
Loading Comments...